This is a list of selected publications.
A complete publication list can be found

Glioma research
  1. Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MCJ, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PAE, Kros JM, French PJ. Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy, a report from the BELOB trial. Cancer Res (2016) 76(3):525-34
  2. Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PHC, Idbaih A, Spliet WGM, den Dunnen WFA, Teepen JL, Wesseling P, Sillevis Smitt PAE, Kros JM, Gorlia T, van den Bent MJ, French PJ. Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. J. Clin Oncol, (2013) 31:328-36 [IF 2011: 18.4]
  3. Pansuriya TC, van Eijk R, de Adamo P, van Ruler M, Kuijjer M, Oosting J, Cleton-Jansen A, van Oosterwijk JG, Verbeke S, Meijer D, van Wezel T, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom L, Daugaard S, Godfraind C, Boon, LM, Vikkula M, Kurek KC, Szuhai K, French PJ, Bovée JVGM. Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature genetics (2011) 43:1256-61 [IF 2011: 35.5]
  4. van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Adbaih A, Sanson M, Sillevis Smitt PAE, French PJ. A Hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Can Res (2011); 17:1748-55 [IF in 2011: 7.7]
  5. Bralten LBC, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge HR, Kros JM, Jansen EEW, Struys EA, Jakobs C, Salomons GS, Diks SH, Peppelenbosch M, Kremer A, Hoogenraad CC, Sillevis Smitt PAE, French PJ. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol. (2011); 69:455-63 [IF in 2011: 11.1]
  6. Kloosterhof NK, Bralten LB, French PJ, van den Bent MJ. IDH1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. (2010); 12-83-91[IF in 2010: 17.8]
  7. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, French PJ. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. (2009); 69:9065-72. Epub 2009 Nov 17. [IF in 2009: 7.5] link
  8. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, van den Bent MJ, Luider TM, Kros JM, van der Spek P, Sillevis Smitt PA. Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res. (2007);67(12):5635-42. [IF in 2007: 7.7] pdf
Neuronal plasticity
  1. O'Connor V, Genin A, Davis S, Karishma KK, Doyere V, De Zeeuw CI, Sanger G, Hunt SP, Richter-Levin G, Mallet J, Laroche S, Bliss TV, French PJ. Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific Pde10A phosphodiesterase splice variants. J. Biol. Chem. (2004): 279 (16):15841-9. [IF in 2004: 6.4] pdf
  2. Jones MW, Errington ML, French PJ, Fine A, Bliss TV, Garel S, Charnay P, Bozon B, Laroche S, Davis S. A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci (2001);4(3):289-96. [IF in 2001: 15.7] link
Cystic Fibrosis
  1. French PJ, van Doorninck JH, Peters RH, Verbeek E, Ameen NA, Marino CR, de Jonge HR, Bijman J, Scholte BJ. A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperaturesensitive processing defect in vivo. J. Clin. Invest. 1996;98(6):1304-12. [IF in 1997: 9.7] pdf
  2. van Doorninck JH, French PJ, Verbeek E, Peters RH, Morreau H, Bijman J, Scholte BJ. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J. (1995) 14, 4403-4411 [IF in 1998: 13.2] pdf
  3. French PJ, Bijman J, Edixhoven M, Vaandrager AB, Scholte BJ, Lohmann SM, Nairn AC, de Jonge HR. Isotype-specific activation of cystic fibrosis transmembrane conductance regulator-chloride channels by cGMPdependent protein kinase II. J. Biol. Chem. 270 (1995), 26626-26631 [IF in 1998: 7.2] pdf
All publications